🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07499804
Recruiting Phase 4

Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes

NCT07499804 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2023-10-01
Last updated
2026-03-30

Condition(s) studied

IVFInfertility, Female

Investigational drug(s) / intervention(s)

Tadalafil 5mg →estradiol valerate 2 mg →

Tadalafil 5mg: phosphodiesterase type 5 (PDE-5) inhibitor

estradiol valerate 2 mg: estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial thickness in day 9 measured by vaginal ultrasound.

Study summary

investigate the effect of different vasodilators as Tadalafil in women with unexplained infertility using IVF

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
43 Years
Healthy volunteers
No
Inclusion Criteria: * has good quality day five frozen embryos. Exclusion Criteria: * hypotension (blood pressure less than 90/50) and * history of stroke or myocardial infarction

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beni-suef university Hospital Banī Suwayf Beni Suweif Governorate Recruiting

More Beni-Suef University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07499804 on ClinicalTrials.gov ↗ ← All trials in Egypt